Karbinal: payments to doctors
Payments that named Karbinal as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $64K
- Providers
- 1,826
- Transactions
- 3,525
- Average per transaction
- $18
The per-transaction average — $18 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 1,826 providers the average total is $35, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Aytu Biopharma, Inc. | $27,130 | 42.3% |
| AYTU Biopharma, Inc. | $25,891 | 40.4% |
| Neos Therapeutics, LP | $7,597 | 11.9% |
| Aytu Bioscience, Inc | $3,482 | 5.4% |